Castle Biosciences (CSTL) 10-Q2021 Q1 Quarterly report

Filed: 10 May 21, 4:49pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Good

New words: added, adjunct, aimed, appointed, atopic, attend, benign, Biden, committee, complement, consummation, Cook, DiffDx, distinction, draft, EGC, entail, expenditure, frame, histopathology, incurrence, indemnification, indeterminate, innovative, issuer, Joseph, Lake, lingering, malignant, match, melanocytic, moderate, move, mutual, myPath, NOL, Olson, onset, posted, RSU, Salt, seasoned, shelf, shift, shown, slight, solution, Tiffany, trend, UM, unmet, unproven, Utah

Removed: acceleration, affiliated, agent, amend, annum, attainment, bankruptcy, bifurcation, bore, borrowing, calculating, catastrophic, certiorari, consolidate, continuance, conversion, converted, count, covenant, declaration, default, disbursed, discrete, dispose, dividend, embedded, encumber, essentially, estimation, excluding, exercisable, exit, feature, Federico, flexibility, floating, foreclosure, geographic, group, hedge, HHS, impairment, LIBOR, lien, liquidated, loan, lowest, LSA, maker, maturity, maximum, measuring, merge, minimum, month, Monzon, nominal, noncompliance, obligated, observable, optional, orderly, originally, Oxford, pledged, prepaid, prepay, prepayment, proceed, promissory, proportion, prospect, quoted, ratio, reborrowed, recognizable, redeem, redeemable, refinance, renegotiate, replacement, repurchase, requested, rescheduled, restructure, revolving, secured, segment, selected, senior, separate, significance, Silicon, structure, sustained, syndicated, temporary, traded, trailing, Trump, unadjusted, Unobservable, unpaid, unrestricted, unsecured, Valley, waiver, warrant

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CSTL transcripts

CSTL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

UNDER SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002, 18 U.S.C. § 1350


In connection with the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021 of Castle Biosciences, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frank Stokes, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date:	May 10, 2021	/s/ Frank Stokes
		Frank Stokes Chief Financial Officer (Principal Financial and Accounting Officer)